EverSource Wealth Advisors’s Standard BioTools LAB Stock Holding History

EverSource Wealth Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.9K	Buy	27,810 +1,344	+5%	+$1.27K	﹤0.01%	2334
2026 Q1	$24.3K	Buy	26,466 +1,388	+6%	+$1.68K	﹤0.01%	2380
2025 Q4	$32.1K	Sell	25,078 -113	-0.4%	-$152	﹤0.01%	2053
2025 Q3	$32.7K	Buy	25,191 +35	+0.1%	+$46	﹤0.01%	2002
2025 Q2	$30.2K	Sell	25,156 -192	-0.8%	-$213	﹤0.01%	1974
2025 Q1	$27.4K	Buy	25,348 +1,537	+6%	+$2.16K	﹤0.01%	1524
2024 Q4	$41.7K	Buy	23,811 +11	+0%	+$20	﹤0.01%	1270
2024 Q3	$45.9K	Hold	23,800	–	–	﹤0.01%	1107
2024 Q2	$53.3K	Hold	23,800	–	–	﹤0.01%	1058
2024 Q1	$59K	Sell	23,800 -4,000	-14%	-$9.66K	﹤0.01%	909
2023 Q4	$61.4K	Hold	27,800	–	–	0.01%	818
2023 Q3	$80.6K	Hold	27,800	–	–	0.01%	645
2023 Q2	$53.7K	Buy	+27,800	New	+$54.9K	0.01%	810
2022 Q2	–	Sell	-917	Closed	-$3K	–	1807
2022 Q1	$3K	Buy	+917	New	+$3.17K	﹤0.01%	1423

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

EverSource Wealth Advisors's LAB Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Standard BioTools (LAB) stake by 5.1% in Q2 2026, buying an estimated $1.27K and bringing the position to 27,810 shares worth $22.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2334.

EverSource Wealth Advisors first reported a position in LAB in Q1 2022 and has held it in 14 quarters since. The position peaked at $80.6K in Q3 2023. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

EverSource Wealth Advisors held 27,810 shares of Standard BioTools worth $22.9K as of Q2 2026.
EverSource Wealth Advisors bought 1,344 Standard BioTools shares in Q2 2026, an estimated $1.27K.
Standard BioTools made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2334 holding.
EverSource Wealth Advisors first reported a position in Standard BioTools in Q1 2022 and has held it in 14 quarters since.
EverSource Wealth Advisors's Standard BioTools position peaked at $80.6K in Q3 2023.
144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.